Literature DB >> 30821553

Ascorbic acid derivative-loaded modified aspasomes: formulation, in vitro, ex vivo and clinical evaluation for melasma treatment.

Mona H Aboul-Einien1, Soha M Kandil2, Ebtsam M Abdou3, Heba M Diab4, Marwa S E Zaki4.   

Abstract

Vitamin C (L-Ascorbic acid) has many favourable effects on the skin such as antioxidant, anti-aging and whitening effects. Its instability and low permeability limit its pharmaceutical use in cosmetic and dermatological products. Instead, Mg ascorbyl phosphate (MAP), an ascorbic acid derivative, has the same effect with higher stability is being used. In this work, a vesicular system, aspasomes, containing MAP was developed and evaluated. Aspasomes are multilayered vesicles formed by amphiphiles molecules, Ascorbyl palmitate (ASP), in combination with cholesterol and charged lipids for drug encapsulation. Here, we investigated the use of lecithin instead of the charged lipid dicetyl phosphate for aspasomes development. Nine formulations were prepared and evaluated for their entrapment efficiency, particle size, polydispersity index (PDI) and zeta potential. Their entrapment efficiency ranged from 33.00 ± 2.27 to 95.18 ± 1.06, while their particle size was from 373.34 ± 60.85 to 464.37 ± 93.46 nm with acceptable PDI (from 0.212 ± 0.068 to 0.351 ± 0.061) and zeta potential (from -37.52 ± 2.42 to -50.36 ± 1.82). Three formulations were selected and evaluated for their drug release, permeation and retention into skin. One formulation was selected to be formulated as aspasomal topical cream and gel. The aspasomal cream was found to have enhanced drug permeation and skin retention over the aspasomal gel as well as the aspasomes formulation. MAP aspasomal cream was evaluated clinically as an effective treatment for melasma against 15% trichloroacetic acid (TCA) and the results recorded that the aspasomal cream showed the greatest degree of improvement regarding the hemi-MASI scores with 35% of patients rating it as excellent treatment. The study showed that MAP aspasomal cream can be considered a novel treatment of melasma which is free of side effects. Its efficacy as a monotherapy is superior to that of chemical peeling using 15% TCA.

Entities:  

Keywords:  Ascorbyl palmitate; aspasomes; clinical; magnesium ascorbyl phosphate; melasma

Year:  2019        PMID: 30821553     DOI: 10.1080/08982104.2019.1585448

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  6 in total

Review 1.  Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment.

Authors:  Fei Qu; Rui Geng; Yijing Liu; Jintao Zhu
Journal:  Theranostics       Date:  2022-04-11       Impact factor: 11.600

2.  Assessment of Nasal-Brain-Targeting Efficiency of New Developed Mucoadhesive Emulsomes Encapsulating an Anti-Migraine Drug for Effective Treatment of One of the Major Psychiatric Disorders Symptoms.

Authors:  Hadel A Abo El-Enin; Rasha E Mostafa; Marwa F Ahmed; Ibrahim A Naguib; Mohamed A Abdelgawad; Mohammed M Ghoneim; Ebtsam M Abdou
Journal:  Pharmaceutics       Date:  2022-02-14       Impact factor: 6.321

3.  Magnesium ascorbyl phosphate vesicular carriers for topical delivery; preparation, in-vitro and ex-vivo evaluation, factorial optimization and clinical assessment in melasma patients.

Authors:  Soha M Kandil; Iman I Soliman; Heba M Diab; Nermeen I Bedair; Marwa H Mahrous; Ebtsam M Abdou
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: comparative clinical study.

Authors:  Caroline Lamie; Enas Elmowafy; Maha H Ragaie; Dalia A Attia; Nahed D Mortada
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

5.  Multidrug Idebenone/Naproxen Co-loaded Aspasomes for Significant in vivo Anti-inflammatory Activity.

Authors:  Nicola d'Avanzo; Maria Chiara Cristiano; Luisa Di Marzio; Maria Chiara Bruno; Donatella Paolino; Christian Celia; Massimo Fresta
Journal:  ChemMedChem       Date:  2022-03-22       Impact factor: 3.540

6.  Targeting Colorectal Cancer Cells with Niosomes Systems Loaded with Two Anticancer Drugs Models; Comparative In Vitro and Anticancer Studies.

Authors:  Shaymaa Wagdy El-Far; Hadel A Abo El-Enin; Ebtsam M Abdou; Ola Elsayed Nafea; Rehab Abdelmonem
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.